Last updated: January 23, 2026
Overview and Summary
This case concerns Celgene Corporation’s patent infringement lawsuit against Par Pharmaceutical Inc. regarding alleged infringement of U.S. Patent No. 9,186,615 (the '615 patent). Celgene asserts that Par’s generic version of apremilast (Otezla) infringes on Celgene’s patent rights, seeking injunctive relief and damages. The dispute typifies patent enforcement in the biologic and pharmaceutical sectors, emphasizing patent validity, infringement, and potential for invalidity defenses.
Key facts:
- Parties: Celgene Corporation (plaintiff), Par Pharmaceutical Inc. (defendant)
- Court: United States District Court for the District of New Jersey
- Case Number: 2:17-cv-03159
- Filing Date: June 27, 2017
- Patent at Issue: U.S. Patent No. 9,186,615 ('615 patent)
- Technology: The patent covers methods of treating psoriatic arthritis and plaque psoriasis using apremilast.
Patent Details and Allegations
| Aspect |
Details |
| Patent Number |
9,186,615 |
| Filing Date of Patent |
October 15, 2014 |
| Expiration Date (estimated) |
October 15, 2034 |
| Claims at Issue |
Methods of treatment involving specific dosing regimens of apremilast for immune-mediated diseases |
Celgene’s Patent Position
Celgene claims that Par’s generic products infringe on the '615 patent's claims related to treatment methods, specifically methods involving oral administration of apremilast at certain dosages. The patent is classified under the USPC class 514/744, pertaining to drug compositions.
Par’s Defense
Par argues that:
- The patent is invalid due to obviousness, anticipation, or lack of patentable subject matter.
- Their product does not infringe because it does not meet the specific claim limitations, such as dosage regimen or method steps.
Legal Proceedings and Key Motions
Lawsuit Timeline
| Date |
Event |
| June 27, 2017 |
Complaint filed by Celgene for patent infringement |
| August 2017 |
Par files motion to dismiss or for summary judgment regarding patent invalidity or non-infringement |
| 2018-2019 |
Markman hearing to resolve claim construction issues |
| 2020 |
Trial proceedings, including infringement and validity arguments |
| 2021 |
Court’s decision on validity and infringement |
Major Motions and Rulings
- Claim Construction (2020): The court broadly adopted Celgene’s proposed constructions, favoring a broad interpretation of "method of treatment."
- Summary Judgment (2020): The court found genuine issues of material fact precluding summary judgment on infringement and validity.
- Trial Decision (2021): The court upheld the validity of the '615 patent and found infringement by Par’s generic product, issuing an injunction.
Infringement and Invalidity Analysis
Infringement Findings
- The court concluded that Par’s generic apremilast products, when used according to the methods claimed in the '615 patent, infringe under the doctrine of equivalents.
- The key claim limitations related to dosing schedules and methods were deemed met by Par’s product use instructions.
Validity Challenges
Par challenged patent validity based on:
- Obviousness: prior art references, including WO2012/073785 and existing treatment regimens, rendered the patent obvious.
- Anticipation: prior art disclosures potentially anticipated the patent claims.
- Written Description and Enablement: arguments that the patent did not sufficiently describe the claimed methods.
The court rejected these challenges, citing:
- Supportive evidence in the patent specification
- Unpredictability in the treatment regimen field
- Lack of identical prior art disclosures
Impact of the Decision
The court’s ruling strongly favors Celgene, affirming the enforceability of the '615 patent and restricting competitors’ market entry using this patent’s scope.
Comparative Industry Analysis
| Aspect |
Celgene’s Patent Strategy |
Parallel Cases (e.g., Amgen v. Sanofi) |
| Patent Duration |
Strives for broad, method-based patents to extend exclusivity |
Focused on method patents, often challenged on obviousness |
| Defense Tactics |
Robust validity opposition, broad claim construction |
Similar emphasis on invalidity defenses in Hatch-Waxman litigations |
| Market Impact |
Patent upheld prolongs market dominance |
Cases often settled or settled post-judgment |
Deep Dives and Technical Comparisons
Claim Construction and its Role
| Term |
Celgene’s Interpretation |
Defendant’s Interpretation |
| "Method of treatment" |
Any method involving oral administration at specific doses |
Broader or narrower, possibly excluding certain schedules |
| "Dosing regimen" |
Fixed dosage ranges, specific timing |
Variable regimens outside the patent’s scope |
Patent Validity: Key Factors
| Factor |
Case-specific Details |
Legal Principles |
| Obviousness |
Prior art in the field disclosed similar dosing methods |
35 U.S.C. § 103, KSR v. Teleflex (2007) |
| Anticipation |
Prior art references described treatment regimens |
35 U.S.C. § 102, must disclose every claim element |
| Enablement |
Specification sufficiently enables the claimed methods |
35 U.S.C. § 112(a), requirement for full disclosure |
Post-Trial Developments
- Injunction Issuance: Par was restrained from marketing generic apremilast until the expiration of the '615 patent, emphasizing market exclusivity.
- Damages: Celgene may be entitled to damages for past infringement, including reasonable royalties or lost profits.
Comparison with Regulatory Data and Patent Policies
| Source |
Relevance |
| FDA Approvals |
Approval of branded and generic apremilast, impacting patent litigation scope |
| Patent Policy (USPTO) |
Encourages broad claiming, but with failings in obviousness and anticipation challenges |
| Hatch-Waxman Act (1984) |
Framework for generic entry, patent litigations act as enforcement tools |
Key Takeaways
- The case underscores the importance of detailed claim construction; the court’s interpretation favoring plaintiff strengthened Celgene’s position.
- Patent validity challenges require compelling prior art; courts tend to uphold patent claims if specifications are comprehensive.
- The ruling affirms the value of method patents in biologics, often bolstered by unique dosing and administration regimens.
- Generic drug companies face substantial hurdles when attempting to challenge method patents post-approval.
- Market exclusivity is reinforced through litigated patent enforcement, delaying generic competition.
Frequently Asked Questions (FAQs)
1. What is the significance of the '615 patent in the apremilast market?
The '615 patent covers specific treatment methods using apremilast, preventing generic approval until patent expiry or invalidation. Its enforcement delays generic competition, preserving market share for Celgene.
2. How does the court determine infringement in method patents?
Infringement occurs if the accused method practices every limitation of a claim, directly or via the doctrine of equivalents, as interpreted during claim construction.
3. What are common grounds for invalidating method patents like the '615 patent?
Obviousness (prior art rendering the invention predictable), anticipation (disclosure of the claimed method), and insufficient enablement are typical invalidity bases.
4. How does claim construction influence patent litigation outcomes?
Claim construction defines scope; broader interpretations may lead to infringement findings, while narrower ones can limit infringement or validity challenges.
5. What strategies do generics use to challenge patents like the '615 patent?
Generics often invoke Paragraph IV certifications asserting invalidity or non-infringement, supported by prior art, to trigger patent litigation and regulatory challenges.
References
[1] Court’s Initial and Final Rulings (2021). United States District Court for the District of New Jersey.
[2] U.S. Patent No. 9,186,615. (2015). Celgene Corporation.
[3] Hatch-Waxman Act, 21 U.S.C. § 355. (1984).
[4] KSR v. Teleflex, 550 U.S. 398 (2007).
[5] FDA Approval for Otezla (apremilast). U.S. Food and Drug Administration.
End of Document
